AST to platelet ratio index (apri) in Patients with metabolic syndrome and its Relation with cardiovascular risk

Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/1778

Full metadata record

DC Field	Value	Language
dc.contributor.author	REG NO: BG0121014	-
dc.date.accessioned	2025-04-26T09:36:33Z	-
dc.date.available	2025-04-26T09:36:33Z	-
dc.date.issued	2024	-
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/1778	-
dc.description.abstract	ABSTRACT Introduction Metabolic syndrome (MetS) encompasses central obesity, elevated triglycerides, reduced HDL cholesterol, high blood sugar, high blood pressure, and insulin resistance, increasing the risk of atherosclerotic cardiovascular disease (ASCVD) and MAFLD. This study investigates the role of the Aspartate Aminotransferase to Platelet Ratio Index (APRI) in predicting cardiovascular risk in subjects with and without MetS. Aims 1. Compare APRI scores between MetS and non-MetS subjects, and various factors influencing APRI. 2. Analyze APRI's role in predicting cardiovascular risk using the Framingham Risk Score and ASCVD score in MetS subjects	en_US
dc.language.iso	en_US	en_US
dc.publisher	KLE Academy of Higher Education and Research, Belagavi	en_US
dc.subject	APRI, Metabolic syndrome, Cardiovascular risk.	en_US
dc.title	AST to platelet ratio index (apri) in Patients with metabolic syndrome and its Relation with cardiovascular risk	en_US
dc.type	Dissertations	en_US
Appears in Collections:	General Medicine MD

Files in This Item:

File	Description	Size	Format
BG0121014.pdf		12.45 MB	Adobe PDF	View/Open